Clinique Universitaire d'Hépato-gastroentérologie, Pôle Digidune, University Hospital Grenoble Alpes, La Tronche, France.
Grenoble Alpes University, Inserm U1041, Grenoble, France.
Dig Dis Sci. 2020 Jan;65(1):301-311. doi: 10.1007/s10620-019-05724-1. Epub 2019 Jul 25.
Data on alcohol-related HCC are limited.
Our aim was to describe the incidence, management, and prognosis of alcohol compared to Hepatitis C (HCV)-related HCC at a national level.
Incident cases of HCC were identified in French healthcare databases between 2009 and 2012 and analyzed retrospectively. Demographic data, type, location, and annual HCC-caseload of the hospitals where patients were first managed were retrieved. Survival of incident cases was computed from the time of diagnosis and adjusted for potential confounding variables.
The study population included 14,060 incident cases of alcohol and 2581 HCV-related HCC. Alcohol-related HCC was more frequent than HCV-related HCC (29.37 and 5.39/100,000 adults/year, respectively) with an heterogeneous distribution on the French territory. The optimal treatment was less frequently curative (20.5% vs 35.9%; p < 0.001), and survival was significantly shorter (9.5 [9.0-10.0] versus 16.8 [15.5-18.7] months p < 0.001) in alcohol compared to HCV-related HCC, with marked variations between regions for a given risk factor. In multivariable analysis in the whole study population, curative treatment was a strong predictor of survival (adjusted HR 0.28 [0.27-0.30] months p < 0.001). Being managed at least once in a teaching hospital during follow-up was independently associated with receiving a curative treatment and survival.
In France, incidence of alcohol-related HCC is high and prognosis is poor compared to HCV-related HCC, with marked variations between regions. These results should guide future health policy initiatives pertaining to HCC care. Importantly, increasing patient' referral in expert centers could increase chances to receive curative treatment and improve outcomes.
目前有关酒精相关性 HCC 的数据有限。
本研究旨在从全国层面描述酒精相关性 HCC 与丙型肝炎病毒(HCV)相关性 HCC 的发病率、治疗方法和预后。
在法国医疗保健数据库中,我们回顾性地分析了 2009 年至 2012 年期间确诊的 HCC 病例。我们获取了患者首次治疗医院的人口统计学数据、HCC 类型、位置以及 HCC 年病例数。采用调整潜在混杂因素后的生存分析来计算 HCC 患者的生存情况。
该研究共纳入 14060 例酒精相关性 HCC 患者和 2581 例 HCV 相关性 HCC 患者。酒精相关性 HCC 的发病率(29.37/10 万成年人/年)高于 HCV 相关性 HCC(5.39/10 万成年人/年),且在法国各地的分布不均。最佳治疗方法的疗效较差(20.5% vs 35.9%;p<0.001),酒精相关性 HCC 患者的生存率明显较短(9.5[9.0-10.0]个月 vs 16.8[15.5-18.7]个月,p<0.001),对于给定的危险因素,各地区之间存在显著差异。在整个研究人群的多变量分析中,根治性治疗是生存的强烈预测因素(调整后的 HR 0.28[0.27-0.30]个月,p<0.001)。在随访期间至少在教学医院接受过一次治疗与接受根治性治疗和生存相关。
在法国,与 HCV 相关性 HCC 相比,酒精相关性 HCC 的发病率较高,预后较差,各地区之间存在显著差异。这些结果应指导未来与 HCC 治疗相关的卫生政策倡议。重要的是,增加患者向专家中心的转诊可以增加接受根治性治疗的机会并改善预后。